Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease
Shots:
- Synlogic regains all rights to develop Synthetic Biotic medicines for all effectors targeting IBD. The termination allows Synlogic to deploy its expertise in strain engineering- quantitative biology- regulatory- and manufacturing of living medicines for expanding its wholly GI-based program portfolio to include IBD
- Regaining WW rights to develop treatments for IBD allows Synlogic to expand its efforts in exploring new areas of biology and potential partnerships
- Under the terms of the original 2015 agreement- AbbVie had an exclusive option to acquire a Synlogic’s subsidiary (IBDCo) while in exchange Synlogic IBDCo received $2M as upfront and up to $16M upon the achievement of milestones
Click here to read full press release/ article | Ref: Synlogic | Image: Synlogic
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
